Compare Intel Corp (INTC) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Medpace Holdings Inc — how do they compare? Intel Corp trades at $105.51 (market cap $566.04B), while Medpace Holdings Inc trades at $617.62 (market cap $16.82B). The key difference: Intel Corp is far larger — about 33.7× Medpace Holdings Inc's market cap, and Intel Corp pays a 2.24% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Medpace Holdings Inc for 14 Days on average.
| INTC | MEDP | |
|---|---|---|
Market Cap | $566.04B | $16.82B |
Volume | 118,475,837 | 223,093 |
Sector | Technology | Health |
52-Week High | $140.94 | $630.19 |
52-Week Low | $33.62 | $393.42 |
Typical Hold Time | 116 Days | 14 Days |
Enterprise Value | $586.85B | $16.44B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $105.75, down 6.52% over the past 24 hours, with a mixed technical picture showing bullish overall signals but bearish moving averages and oscillators. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.42 beating expectations of $0.21. However, Intel faces fundamental challenges with negative net income margins (-19.79%) and elevated valuation ratios (P/E of 904.17), though operating cash flow improved to $9.7 billion in 2025.
Intel's turnaround story shows early signs of progress with strong foundry revenue growth and government support, but profitability remains a concern. The stock offers potential upside to the analyst consensus price target of $111.72, though execution risks in the competitive semiconductor space and high debt levels pose significant challenges for investors seeking sustained recovery.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
